IMAP Brief Statement Comparing Injectable Contraceptives: depot medroxyprogesterone acetate (DMPA) versus norethisterone enanthate (NET-EN)

Introduction

IMAP has developed this Statement because of recent shortages of DMPA in many countries. It provides, firstly, information and guidance to IPPF Member Associations which may need to procure NET-EN instead of DMPA and, secondly, offers guidance on how to enable clients to make a smooth transition from DMPA to NET-EN when medication shortages occur.

What are DMPA and NET-EN?

DMPA and NET-EN are both progestogen-only injectable contraceptives. DMPA is the most widely used progestogen-only injectable and is also known as Depo, Depo Provera, Megestron and Petogen. NET-EN is also known as norethindrone enanthate, Noristerat and Syngestal. They are both available as an intramuscular injection, and DMPA is also available in some countries as a subcutaneous formulation (known as depo-subcu or Sayana Press).

What are the main similarities and key differences between DMPA and NET-EN?

The key characteristics of DMPA and NET-EN are highlighted in Table 1.

Table 1: Key characteristics of DMPA and NET-EN

<table>
<thead>
<tr>
<th>CHARACTERISTIC</th>
<th>DMPA</th>
<th>NET-EN</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is the dosage?</td>
<td>150mg intramuscular OR 104mg subcutaneous</td>
<td>200mg intramuscular</td>
</tr>
<tr>
<td>What is the time interval between injections?</td>
<td>3 months</td>
<td>2 months</td>
</tr>
<tr>
<td>How early can the client have the next injection?</td>
<td>2 weeks</td>
<td>2 weeks</td>
</tr>
<tr>
<td>How late can the client have the next injection?</td>
<td>4 weeks</td>
<td></td>
</tr>
<tr>
<td>What are the typical bleeding patterns in first year?</td>
<td>Irregular and prolonged bleeding at first, followed by no bleeding or infrequent bleeding. About 40% of users have no monthly bleeding after one year.</td>
<td>Irregular or prolonged bleeding in the first six months, but the bleeding episodes are shorter than with DMPA. After six months, the bleeding patterns are similar to those with DMPA. 30% of users have no monthly bleeding after one year.</td>
</tr>
<tr>
<td>What is the average weight gain?</td>
<td>1–2kg per year</td>
<td>1–2kg per year</td>
</tr>
<tr>
<td>What is the pregnancy rate?</td>
<td>About three pregnancies per 100 women in the first year</td>
<td>Assumed to be similar to DMPA</td>
</tr>
<tr>
<td>How long is the average delay in becoming pregnant after stopping injections?</td>
<td>Four months longer than for women who use other contraceptive methods</td>
<td>One month longer than women who use other contraceptive methods</td>
</tr>
</tbody>
</table>

1 IMAP is IPPF’s International Medical Advisory Panel.
Interval between injections
The interval between injections for DMPA is three months and for NET-EN is two months. The World Health Organization recommends that either injection can be given up to two weeks early.3

Time-lapse after scheduled repeat injections
The latest guidelines from the WHO Selected Practice Recommendations state that DMPA can be given up to four weeks late without the need for additional contraceptive protection while the corresponding time-lapse for NET-EN is up to two weeks late. This is based on the very low risk of ovulation within the four weeks after the scheduled repeat injection of DMPA and within the two weeks after the scheduled repeat injection for NET-EN. Women can receive either injection at any time as long as the provider is reasonably certain the woman is not pregnant4 but she will need to use additional contraceptive protection or abstain from sex for seven days after the injection if it is given beyond the recommended time-lapse.

Evidence on DMPA versus NET-EN
• DMPA and NET-EN are considered equivalent in the WHO Medical Eligibility Criteria for Contraceptive Use and all recommendations are the same for the two methods.
• In a systematic review of the literature, only two studies were found that directly compared DMPA and NET-EN.
• In these studies, women using DMPA were more likely to develop amenorrhea, although the duration of bleeding and spotting events was the same in each group. The remainder of the clinical effects showed little difference between the two methods.

Recommendations
• Member Associations can provide either DMPA or NET-EN as injectable contraception as part of the available contraceptive method mix because the mechanism of action, medical eligibility criteria and side-effects of the two medications are similar.
• If stock-out occurs of one type of injectable progestogen-only contraception, and the other type is available as an alternative, it is safe for women to stop using one and start using the alternative.
• While not routinely recommended, if it becomes necessary to switch from DMPA to NET-EN – or vice versa – the switch should be made at the time of the scheduled repeat injection.
